



VILIN BIO MED LIMITED
An ISO 9001-2008 & GMP certified Company

May 29, 2024

To,
National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex, Bandra (East)
Mumbai – 400051

Symbol- VILINBIO

Sub: Outcome of the Board Meeting – May 29, 2024

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

This is to inform you that pursuant to the Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, the Board of Directors of the Company in its Meeting held today i.e. Wednesday, May 29, 2024 has considered and approved the following:

1. The Standalone Financial Results for the Half-year and Financial Year ended March 31, 2024 along with the Auditors Report with Unmodified Opinion on the Financial Results of the Company issued by M/s PPKG & Co., Statutory Auditors of the Company. (Copy of Financial Results with Auditors Report are enclosed).
2. Resignation of Ms. Padmaja Kalyani Sadhanala (DIN: 03096445) as Director of the Company. Ms. Padmaja Kalyani Sadhanala Director of the Company has resigned from the position of Director due to her pre-occupations.

The Board accepted the resignation of Ms. Padmaja Kalyani Sadhanala as Director of the Company and took on record the appreciation of her work during the period of office as the Director of the Company.

The details as required under SEBI (Listing Obligations and Disclosure Requirements), 2015 is enclosed and marked as Annexure — A.

In furtherance to the intimation filed by the Company dated May 20, 2024 the Trading Window for trading in the Securities of the Company, which was closed from April 1, 2024 to till 48 hours after the declaration of the Audited Standalone Financial Results, shall be opened after the expiry of forty-eight hours after declaration of the said Results.

Registered Office: Sy. No. 115/GF/J, Hanumanji Colony, Brig Sayeed Road, Bowenpally, Hyderabad – 500009, Telangana.
Manufacturing Unit: Unit-II, Khasra No. 85, Madhopur Village, Roorkee, Haridwar- 247667, Uttarakhand.

Tel No: 040- 79618843

CIN: L24230AP2005PLC046689

E-mail: cs@vilinearbiomed.co.in

GST: 36AACCV1433D1ZR

Website: www.vilinearbiomed.co.in



VILIN BIO MED LIMITED

An ISO 9001-2008 & GMP certified Company

The Meeting of the Board of Directors was conducted at the Corporate Office of the Company, which commenced at 3:00 P.M. and concluded at 4:40 P.M.

The Financial Results are also hosted on the website of the company at www.vilinbiomed.co.in and National Stock Exchange of India Limited at www.nseindia.com

We request you to kindly take the above information on record.

Thanking You

Yours Sincerely

For Vilin Bio Med Limited

Viswa Prasad Sadhanala
Managing Director

Encl: as above



Registered Office: Sy. No. 115/GF/J, Hanumanji Colony, Brig Sayeed Road, Bowenpally, Hyderabad – 500009, Telangana.
Manufacturing Unit: Unit-II, Khasra No. 85, Madhopur Village, Roorkee, Haridwar- 247667, Uttarakhand.

Tel No: 040- 79618843

CIN: L24230AP2005PLC046689

E-mail: cs@vilinbiomed.co.in

GST: 36AACCV1433D1ZR

Website: www.vilinbiomed.co.in



VILIN BIO MED LIMITED

An ISO 9001-2008 & GMP certified Company

VILIN BIO MED LIMITED

Registered Office : Sy.No.115/GF/J Haanumanji Colony, Brig Syed Road, Bowenpally, Hyderabad - 500003

CIN : U24230TG2005PLC046689

Statement of Audited Financial Results for the half year ended March 31,2024

(Rs. in Lakhs)

	Particulars	Half - Year Ended			Year Ended	
		31-Mar	30-Sep	31-Mar	31-Mar	31-Mar
		2024	2023	2023	2024	2023
		Audited	Unaudited	Audited	Audited	Audited
I	Income					
(a)	Revenue from Operations	815.92	764.57	821.49	1,580.49	1,231.30
(b)	Other Income	21.62	10.81	2.44	32.43	2.44
	Total Revenue	837.54	775.38	823.93	1,612.92	1,233.74
II	Expenses					
(a)	Cost of Materials Consumed	796.51	483.04	478.75	1,279.55	709.53
(b)	Purchase of Stock in Trade					
(c)	Changes in Inventories of Stock-in-Trade, Work in Progress and Finished Goods	21.06	-	(2.92)	21.06	7.58
(d)	Employee Benefit Expenses	44.73	35.65	42.06	80.38	77.74
(e)	Finance Cost	40.82	37.76	32.90	78.58	64.84
(f)	Depreciation and Amortisation Expenses	5.39	7.62	8.38	13.01	16.76
(g)	Other Expenses	10.84	106.99	156.76	117.83	179.12
	Total Expenses	919.35	671.06	715.93	1,590.41	1,055.58
III	Profit / (Loss) Before Exceptional Items and Tax	(81.80)	104.32	108.00	22.52	178.16
	Exceptional Items		-	-		-
	Profit / (Loss) Before Tax	(81.80)	104.32	108.00	22.52	178.16
IV	Tax Expense:					
(1)	Current Tax	(22.01)	27.12	35.29	5.11	52.83
(2)	Deferred Tax	0.87	0.29	3.34	1.16	0.84
	Profit / (Loss) for the Period from Continuing Operations	(60.67)	76.91	69.37	16.24	124.50
	Profit / (Loss) from Discontinued Operations			-		
	Tax Expense of Discontinued Operations			-		
	Profit / (Loss) from Discontinued Operations (After Tax)			-		-
V	Profit / (Loss) for the Period	(60.67)	76.91	69.37	16.24	124.50
	Other Comprehensive Income					
A (i)	Items that will not be reclassified to Profit or Loss			-		-
(ii)	Income Tax relating to items that will not be reclassified to Profit or Loss			-		-
B (i)	Items that will be reclassified to Profit or Loss			-		-
(ii)	Income Tax relating to items that will be reclassified to Profit or Loss			-		-
	Total Comprehensive Income for the period (Comprising Profit / (Loss) and Other Comprehensive Income for the period)			-		-
VI	Earnings Per Equity Share - Basic and Diluted	(0.43)	0.55	0.70	0.12	1.25

Registered Office: Sy. No. 115/GF/J, Hanumanji Colony, Brig Sayeed Road, Bowenpally, Hyderabad - 500009, Telangana.

Manufacturing Unit: Unit-II, Khasra No. 85, Madhopur Village, Roorkee, Haridwar- 247667, Uttarakhand.

Tel No: 040- 79618843

CIN: L24230TG2005PLC046689

E-mail: cs@vilinbiomed.co.in

GST: 36AACC1433D1ZR

Website: www.vilinbiomed.co.in



VILIN BIO MED LIMITED

An ISO 9001-2008 & GMP certified Company

Notes to Accounts:

- 1 The above audited standalone financial results of Vilin Bio /med Limited ("the Company") as reviewed by the Audit Committee and has been approved by the Board of Directors of the Company at their respective meeting held on May 29, 2024. The Statutory Auditors of the Company have carried out the limited review on standalone financial results and expressed on unmodified conclusion thereon.
- 2 The Financial results has been prepared in accordance with the accounting standards prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounting) Rules, 2014 (as amended) and other recognised accounting practices and policies as applicable.
- 3 The financial results and other financial information for the corresponding Year Ended March 2024 have not been subject to audit by the statutory auditor. However, the management has exercised necessary due diligence and ensure that the financial result for this period provide a true and fair review of the Company's affair.
- 4 The Company's business activity falls within a single business segment i.e., manufacturing of pharmaceutical products. The company operated only in one geographical segment i.e., domestic segment.
- 5 The Company has completed fresh issue of Equity shares by Initial Public Offer ("IPO") of Rs.1200.00 Lakhs of 40,00,000 equity shares of face value Rs. 10/- each at an issue price of Rs.30/- per equity share. The equity shares of the Company were listed on National Stock Exchange of India Ltd ("NSE") Emerge Platform on June 30,2023. The details of utilization of the net proceeds as mentioned below:

Particulars	As per the prospectus	(RS.IN.LAKHS)	
		Utilised till 30.09.2023	Balance
Meeting additional working capital requirements	850.00	690.00	160.00
General Corporate purpose	250.00	50.00	200.00
Public Issue Expenses	100.00	97.00	3.00
Total	1200.00	837.00	363.00

* The Un-utilised amount of Rs. 516.00 Lakhs is maintained in the Bank Account with Scheduled Commercial Bank.

- 6 Previous period's / year's figures have been re-grouped / re-arranged wherever necessary to correspond with the Current year's Classification / Disclosures.

By Order of the Board
For Vilin Bio Med Limited

Place: Hyderabad
Date: 29.05.2024

Viswa Prasad Sadhanala
(Managing Director)
DIN: 08068933

Registered Office: Sy. No. 115/GF/J, Hanumanji Colony, Brig Sayeed Road, Bowenpally, Hyderabad – 500009, Telangana.
Manufacturing Unit: Unit-II, Khasra No. 85, Madhopur Village, Roorkee, Haridwar- 247667, Uttarakhand.

Tel No: 040- 79618843

CIN: L24230TG2005PLC046689

E-mail: cs@vilinbiomed.co.in

GST: 36AACCV1433D1ZR

Website: www.vilinbiomed.co.in



VILIN BIO MED LIMITED
An ISO 9001-2008 & GMP certified Company

VILIN BIO MED LIMITED
Registered Office : Sy.No.115/GF/J Haanumanji Colony, Brig Syed Road, Bowenpally, Hyderabad - 500003
CIN : U24230TG2005PLC046689

Statement of Audited Financial Results for the year ended March 31,2024

(Rs. in Lakhs)

Particulars	As at 31-Mar-2024	As at 31-Mar-2023
	(Audited)	(Audited)
I EQUITY AND LIABILITIES		
(A) Shareholder's Funds		
(a) (a) Share Capital	1,395.00	995.00
(b) (b) Reserves and Surplus	889.00	72.76
(c) (c) Money received against Share Warants	-	-
	2,284.00	1,067.76
(B) Non-Current Liabilities		
(a) Long Term Borrowings	20.87	43.12
(b) Other Long Term Liabilities	-	-
(c) Deferred Tax Liabilities (Net)	8.16	7.00
(d) Other Non-Current Liabilities	-	-
	29.03	50.12
(C) Current Liabilities		
(a) Short Term Borrowings	662.12	450.00
(b) Trade Payables		
(i) Total Outstanding due to MSME Unit	-	-
(ii) Total Outstanding dues other than MSME Unit	195.34	118.94
(c) Other Current Liabilities	11.89	26.43
(d) Short Term Provisions	58.01	54.33
	927.36	649.68
Total Equity and Liabilities	3,240.39	1,767.56
II ASSETS		
(A) Non-Current Assets		
(a) Property, Plant and Equipment and Intangible Assets		
(i) Property, Plant and Equipment	138.27	151.15
(ii) Capital work-in-progress		
(iii) Intangible Assets		
(b) Non - Current Investments		
(c) Deferred Tax Assets (Net)		-
(d) Long Term Loans and Advances	466.06	94.84
(e) Other Non-Current Receivables	774.50	716.13
	1,378.83	962.12
(B) Current Assets		
(a) Inventories	446.75	87.88
(b) Trade Receivables	568.41	560.05
(c) Cash and Cash Equivalents	604.94	3.45
(d) Short Term Loans and Advances	117.59	71.88
(e) Other Current Assets	123.87	82.18
	1,861.56	805.44
Total Assets	3,240.39	1,767.56

By Order of the Board
For Vilin Bio Med Limited

Place: Hyderabad
Date: 29.05.2024

Viswa Prasad Sadhanala
Managing Director
DIN: 08068933

Registered Office: Sy. No. 115/GF/J, Hanumanji Colony, Brig Sayeed Road, Bowenpally, Hyderabad – 500009, Telangana.
Manufacturing Unit: Unit-II, Khasra No. 85, Madhopur Village, Roorkee, Haridwar- 247667, Uttarakhand.

Tel No: 040- 79618843

CIN: L24230TG2005PLC046689

E-mail: cs@vilinbiomed.co.in

GST: 36AACCV1433D1ZR

Website: www.vilinbiomed.co.in



VILIN BIO MED LIMITED

An ISO 9001-2008 & GMP certified Company

VILIN BIO MED LIMITED

Registered Office : Sy.No.115/GF/J Haanumanji Colony, Brig Syed Road, Bowenpally, Hyderabad - 500003

CIN : U24230TG2005PLC046689

Statement of Audited Financial Results for the year ended March 31,2024

(Rs. in Lakhs)

CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2024		
Particulars	As at 31-Mar-2024	As at 31-Mar-2023
Cash Flow from Operating Activities		
Net Profit Before Tax and Extra-ordinary Items	22.53	178.15
Adjustment For		
Depreciation	13.01	16.76
Foreign Exchange		
Gain or Loss on Sale of Fixed Assets		
Gain or Loss on Sale of Investment		
Finance Cost	78.58	
Dividend Income		
Other adjustment of Non-Cash Item		
Other adjustment to reconcile Profit		
	91.59	16.76
Adjustment For working Capital Change		
Adjustment for Increase/Decrease in Inventories	(358.87)	140.50
Adjustment for Increase/Decrease in Trade Receivables	(8.36)	(208.74)
Adjustment for Increase/Decrease in Other Current Assets	(41.69)	(59.36)
Adjustment for Increase/Decrease in Other Non Current Assets	(58.37)	(289.16)
Adjustment for Increase/Decrease in Short Term Borrowings	212.12	
Adjustment for Increase/Decrease in Long term Loans and Advances	(371.22)	
Adjustment for Increase/Decrease in Short Term Loans and advances	(45.71)	(10.36)
Adjustment for Increase/Decrease in Trade Payables	76.40	54.82
Adjustment for Increase/Decrease in Other Current Liabilities	(14.54)	14.87
Adjustment for Provisions	3.68	50.33
Total Adjustment For Working Capital (B)	(606.56)	(307.10)
Total Adjustment to reconcile Profit (A+B)	(514.97)	(290.34)
Net Cash Flow from (Used in) Operations	(492.44)	(112.19)
Dividend Received		
Interest Received	(32.43)	
Interest Paid	-	
Income Tax Paid / Refund	(5.11)	(53.67)
Net Cash Flow from (used in) operation before Extra-ordinary Items	(529.98)	(165.85)
Proceeds from Extra-ordinary Items		
Payment for Extra-ordinary Items		
Net Cash Flow from Operating Activities	(529.98)	(165.85)
Cash Flows from Investing Activities		
Proceeds from Fixed Assets		(2.95)
Proceeds from Investment or Equity Instruments		
Purchase of Fixed Assets	0.13	
Purchase of Investments or Equity Instruments		
Interest Received	32.43	
Dividend Received		

Registered Office: Sy. No. 115/GF/J, Hanumanji Colony, Brig Sayeed Road, Bowenpally, Hyderabad – 500009, Telangana.

Manufacturing Unit: Unit-II, Khasra No. 85, Madhopur Village, Roorkee, Haridwar- 247667, Uttarakhand.

Tel No: 040- 79618843

CIN: L24230TG2005PLC046689

E-mail: cs@vilinbiomed.co.in

GST: 36AACCV1433D1ZR

Website: www.vilinbiomed.co.in



VILIN BIO MED LIMITED

An ISO 9001-2008 & GMP certified Company

Cash Receipt from Sale of Interest in Joint Venture		
Cash Payment to acquire Interest in Joint Venture		
Cash Flow from loosing Control of Subsidiaries		
Cash Payment for acquiring Control of Subsidiaries		
Proceeds from Government Grant		
Other Inflow / Outflow of Cash		
Net Cash Flow from (Used in) in Investing Activities before Extra-ordinary Items	32.30	(2.95)
Proceeds from Extra Ordinary Items		
Payment for Extra Ordinary Item		
Net Cash Flow from (Used in) in Investing Activities	32.30	(2.95)
Cash Flows from Financial Activities		
Proceeds from Issue of Shares	400.00	204.00
Proceeds from Issuing shares for security premium	800.00	-
Proceeds from Issue of Debenture / Bonds / Notes		
Redemption of Preference Shares		
Redemption of Debentures		
Proceeds from other Equity Instruments		
Proceeds from Borrowing		(6.56)
Repayment of Borrowing	22.25	29.09
Dividend Paid		
Interest Paid	78.58	
Income Tax Paid / Refund		
Net Cash Flow from (Used in) in Financial Activities before Extra-ordinary Items	1,099.17	168.35
Proceeds from Extra-ordinary Items		
Payment for Extra-ordinary Items		
Net Cash Flow from (Used in) in Financial Activities	1,099.17	168.35
Net Increase (Decrease) in Cash and Cash Equivalents before effect of Exchange Rate changes	601.49	(0.45)
Effect of Exchange Rate change on Cash and Cash Equivalents		
Net Increase (Decrease) in Cash and Cash Equivalents	601.49	(0.45)
Cash and Cash Equivalents at beginning of period	3.45	3.90
Cash and Cash Equivalents at end of period	604.94	3.45

By Order of the Board
For Vilin BioMed Limited

Hyderabad
Date: 29.05.2024

Viswa Prasad Sadhanala
(Managing Director)
DIN : 08068933

Registered Office: Sy. No. 115/GF/J, Hanumanji Colony, Brig Sayeed Road, Bowenpally, Hyderabad – 500009, Telangana.
Manufacturing Unit: Unit-II, Khasra No. 85, Madhopur Village, Roorkee, Haridwar- 247667, Uttarakhand.

Tel No: 040- 79618843

CIN: L24230TG2005PLC046689

E-mail: cs@vilinbiomed.co.in

GST: 36AACCV1433D1ZR

Website: www.vilinbiomed.co.in

**Auditor's Report on Standalone Financial Results pursuant to Regulation 33 of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015**

To
The Board of Directors
Vilin Bio Med Limited
Hyderabad

Report on the Audit of the Standalone Financial Results

Opinion

We have audited the accompanying Standalone Financial Results of **Vilin Bio Med Limited** ("the Company") for the half-year ended March 31, 2024 and the Year-to-date Results for the period from April 1, 2023 to March 31, 2024 attached herewith being submitted by the Company, pursuant to requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations") including relevant Circulars issued by the Securities and Exchange Board of India (SEBI) from time to time.

In our opinion and to the best of our information and according to the explanations given to us, the Standalone Financial Statements:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. gives a true and fair view in conformity with the Recognition and Measurement Principles laid down in the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and other Accounting Principles generally accepted in India, of the Net Profit, Other Comprehensive Income and Other Financial Information of the Company for the Half-year period ended March 31, 2024 as well as for the Year-to-Date Results for the period from April 1, 2023 to March 31, 2024.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Results* section of the Report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India, together with the ethical requirements that are relevant to our audit of the Financial Results, under the provisions of the Act and Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the Audit Evidence obtained by us is sufficient and appropriate to provide a basis for our Opinion.

Management's Responsibilities for the Standalone Financial Results

This statements includes the Half-yearly Financial Results as well as Year-to-Date Standalone Financial Results have been prepared on basis of the Standalone Annual Financial Statements. The Company's Board of Directors are responsible for the preparation of these Financial Results that give a true and fair view of the Net Profit and Other Comprehensive Income and Other Financial Information in accordance with the Recognition and Measurement Principles, as laid down in Indian Accounting Standards, as prescribed under Section 133 of the Act read with relevant Rules issued thereunder and other Accounting Principles generally accepted in India and in compliance with the Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate Accounting Records in accordance with the provisions of the Act for safeguarding of the Assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate Accounting Policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate Internal Financial Controls that were operating effectively for ensuring the accuracy and completeness of the Accounting Records, relevant to the preparation and presentation of the Financial Results, that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors are responsible for assessing the Company's ability to continue as a 'Going Concern', disclosing, as applicable, matters related to going concern and using the 'Going Concern' basis of accounting, unless the Board of Directors either intends to liquidate the Company or to cease the operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Financial Reporting Process of the Company.

Auditor's Responsibilities

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results as a whole, are free from material misstatement, whether due to fraud or error, and to issue an Auditor's Report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an Audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Standalone Financial Results.

As part of an Audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the Audit. We also:

- Identify and assess the risks of material misstatement of the Standalone Financial Results, whether due to fraud or error, design and perform Audit Procedures responsive to those risks, and obtain Audit Evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of Internal Controls.
- Evaluate the appropriateness of the Accounting Policies used and the reasonableness of Accounting Estimates made by the Board of Directors.

- Evaluate the appropriateness and reasonableness of the disclosures made by the Board of Directors in terms of requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the 'Going Concern' basis of accounting and, based on the Audit Evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a Going Concern. If we conclude that a material uncertainty exists, we are required to draw attention in our Auditor's Report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the Audit Evidence obtained up to the date of our Auditor's Report. However, future events or conditions may cause the Company to cease to continue as a Going Concern.
- Evaluate the overall presentation, structure, and content of the Standalone Financial Results, including the disclosures, and whether the Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in the Internal Controls that we identify during our Audit.


We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The Statement includes the Results for half-year ended March 31, 2024 being the balancing figure between the Audited Figures in respect of the full Financial Year ended March 31, 2024 and the published Year-to-date figures up to half-year of the Current Financial Year, which were subjected to Limited Review by us, as required under the Listing Regulations.

Date: May 29, 2024
Place: Hyderabad

For PPKG & Co
Chartered Accountants
FRN: 009655S



Girdhari Lal Toshniwal
(Partner)

M. No. 205140

UDIN: 24205140BKALIZ 2286



VILIN BIO MED LIMITED
An ISO 9001-2008 & GMP certified Company

May 29, 2024

To
The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C / Block – G
Bandra Kurla Complex
Bandra (East)
Mumbai – 400051

Dear Sir / Madam,

Ref: Scrip Code: VILINBIO ISIN: INE0L4V01013

Sub: Declaration on Audit Report with Unmodified Opinion in pursuant to Regulation 33(3) (d) of the Securities Exchange Board of India (Listing Obligation and Disclosure Requirements), Regulations, 2015

Declaration

I, Viswa Prasad Sadhanala, Whole-time Director of Vilin Bio Med Limited (“Company”) hereby confirm and declare that M/s. PPKG & Co, Chartered Accountants (Firm Registration No. 009655S) Statutory Auditors of the Company, have given the Audit Report with Unmodified Opinion on the Audited Financial Results (Standalone & Consolidated) for the year ended March 31, 2024.

Kindly take the declaration on your records.

Yours’ Faithfully

For Vilin Bio Med Limited

Viswa Prasad Sadhanala
Managing Director
DIN: 08068933

Registered Office: Sy. No. 115/GF/J, Hanumanji Colony, Brig Sayeed Road, Bowenpally, Hyderabad – 500009, Telangana.
Manufacturing Unit: Unit-II, Khasra No. 85, Madhopur Village, Roorkee, Haridwar- 247667, Uttarakhand.

Tel No: 040- 79618843

CIN: L24230TG2005PLC046689

E-mail: cs@vilinbiomed.co.in

GST: 36AACCV1433D1ZR

Website: www.vilinbiomed.co.in



VILIN BIO MED LIMITED

An ISO 9001-2008 & GMP certified Company

ANNEXURE – A

Details as required under Regulation 30-Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09,2015

Resignation of Ms. Padmaja Kalyani Sadhanala (DIN: 03096445) as Director of the Company.

Sl No	Particulars	Details
1	Reason for Change viz., Appointment, Resignation, Removal, Death or otherwise	Mrs. Padmaja Kalyani Sadhanala has tendered her resignation from the post of Non-Executive Director of the Company due to personal reasons and there are no material reasons for the resignation.
2	Date of Appointment / Cessation (as applicable) & Terms of Appointment	Resigned w.e.f. May 29, 2024
3	Brief Profile (in case of appointment)	Not Applicable
4	Disclosure of relationship between the Directors (in case of appointment as a Director)	Not Applicable
5	Disclosure in terms of Regulation 30 read with Clause 7B of Part-A of the Schedule-III of the Regulations	As enclosed

Names of the Listed Entities in which Mrs. Padmaja Kalyani Sadhanala holds Directorships, indicating the category of Directorship and Membership of the Board Committees before the resignation becoming effective:

Sl No	Name of the Listed Entity	Directorship	Membership of the Board Committees
1	Vilin Bio Med Limited	Non-Executive Director	Nomination and Remuneration Committee

Mrs. Padmaja Kalyani Sadhanala automatically ceased to be a Member of the aforesaid Committee in Vilin Bio Med Limited, with effect from May 29, 2024.

Registered Office: Sy. No. 115/GF/J, Hanumanji Colony, Brig Sayeed Road, Bowenpally, Hyderabad – 500009, Telangana.
Manufacturing Unit: Unit-II, Khasra No. 85, Madhopur Village, Roorkee, Haridwar- 247667, Uttarakhand.

Tel No: 040- 79618843

CIN: L24230AP2005PLC046689

E-mail: cs@vilinbiomed.co.in

GST: 36AACCV1433D1ZR

Website: www.vilinbiomed.co.in

Date : 29.05.2024

To,

The Board of Directors,
M/s VILIN BIO MED LIMITED
Secunderabad-500009

Dear Sir,

Sub :- Resignation from Directorship

I hereby tender my resignation from the Directorship of VILIN BIO MED LIMITED due to personal and unavoidable circumstances, I do hereby tender my resignation from the Directorship of the Company with immediate effect. Kindly accept this letter as my resignation with immediate effect from the post of Director of the Company and relieve me of my duties.

Further, I also confirmed that there are no other material reasons for my resignation as a director of the company.

Kindly accept this letter as my resignation with immediate effect from the post of Director of the Company and relieve me of my duties.

Kindly acknowledge the receipt of this resignation letter and arrange to submit the necessary forms with the office of the Registrar of Companies, to that effect.

Thanking You,
Yours faithfully



(Padmaja Kalyani Sadhanala)
DIN: 03096445